Logo image of LEGN

LEGEND BIOTECH CORP-ADR (LEGN) Stock Overview

USA - NASDAQ:LEGN - US52490G1022 - ADR

32.82 USD
-0.06 (-0.18%)
Last: 9/25/2025, 8:00:02 PM
32.82 USD
0 (0%)
After Hours: 9/25/2025, 8:00:02 PM

LEGN Key Statistics, Chart & Performance

Key Statistics
52 Week High51.77
52 Week Low27.34
Market Cap6.02B
Shares183.45M
Float90.53M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.75
PEN/A
Fwd PE53.56
Earnings (Next)11-10 2025-11-10/bmo
IPO06-04 2020-06-04
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


LEGN short term performance overview.The bars show the price performance of LEGN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6

LEGN long term performance overview.The bars show the price performance of LEGN in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of LEGN is 32.82 USD. In the past month the price decreased by -5.5%. In the past year, price decreased by -33.41%.

LEGEND BIOTECH CORP-ADR / LEGN Daily stock chart

LEGN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.64 386.06B
AMGN AMGEN INC 12.43 145.99B
GILD GILEAD SCIENCES INC 14.34 137.72B
VRTX VERTEX PHARMACEUTICALS INC 22.54 97.91B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.93B
REGN REGENERON PHARMACEUTICALS 12.17 58.88B
ARGX ARGENX SE - ADR 76.71 43.52B
ONC BEONE MEDICINES LTD-ADR 5.75 39.08B
INSM INSMED INC N/A 28.66B
BNTX BIONTECH SE-ADR N/A 23.58B
NTRA NATERA INC N/A 22.46B
BIIB BIOGEN INC 8.47 19.89B

About LEGN

Company Profile

LEGN logo image Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 2,800 full-time employees. The company went IPO on 2020-06-04. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Company Info

LEGEND BIOTECH CORP-ADR

2101 Cottontail Lane

Somerset NEW JERSEY 08873 US

CEO: Ying Huang

Employees: 2600

LEGN Company Website

LEGN Investor Relations

Phone: 17328505598

LEGEND BIOTECH CORP-ADR / LEGN FAQ

What is the stock price of LEGEND BIOTECH CORP-ADR today?

The current stock price of LEGN is 32.82 USD. The price decreased by -0.18% in the last trading session.


What is the ticker symbol for LEGEND BIOTECH CORP-ADR stock?

The exchange symbol of LEGEND BIOTECH CORP-ADR is LEGN and it is listed on the Nasdaq exchange.


On which exchange is LEGN stock listed?

LEGN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LEGEND BIOTECH CORP-ADR stock?

26 analysts have analysed LEGN and the average price target is 77.3 USD. This implies a price increase of 135.53% is expected in the next year compared to the current price of 32.82. Check the LEGEND BIOTECH CORP-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LEGEND BIOTECH CORP-ADR worth?

LEGEND BIOTECH CORP-ADR (LEGN) has a market capitalization of 6.02B USD. This makes LEGN a Mid Cap stock.


How many employees does LEGEND BIOTECH CORP-ADR have?

LEGEND BIOTECH CORP-ADR (LEGN) currently has 2600 employees.


What are the support and resistance levels for LEGEND BIOTECH CORP-ADR (LEGN) stock?

LEGEND BIOTECH CORP-ADR (LEGN) has a support level at 32.8 and a resistance level at 33.77. Check the full technical report for a detailed analysis of LEGN support and resistance levels.


Is LEGEND BIOTECH CORP-ADR (LEGN) expected to grow?

The Revenue of LEGEND BIOTECH CORP-ADR (LEGN) is expected to grow by 68.18% in the next year. Check the estimates tab for more information on the LEGN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy LEGEND BIOTECH CORP-ADR (LEGN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LEGEND BIOTECH CORP-ADR (LEGN) stock pay dividends?

LEGN does not pay a dividend.


When does LEGEND BIOTECH CORP-ADR (LEGN) report earnings?

LEGEND BIOTECH CORP-ADR (LEGN) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of LEGEND BIOTECH CORP-ADR (LEGN)?

LEGEND BIOTECH CORP-ADR (LEGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.75).


What is the Short Interest ratio of LEGEND BIOTECH CORP-ADR (LEGN) stock?

The outstanding short interest for LEGEND BIOTECH CORP-ADR (LEGN) is 8.68% of its float. Check the ownership tab for more information on the LEGN short interest.


LEGN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LEGN Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to LEGN. The financial health of LEGN is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LEGN Financial Highlights

Over the last trailing twelve months LEGN reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS decreased by -12.18% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -19.25%
ROE -31.42%
Debt/Equity 0.37
Chartmill High Growth Momentum
EPS Q2Q%-580%
Sales Q2Q%36.74%
EPS 1Y (TTM)-12.18%
Revenue 1Y (TTM)74.75%

LEGN Forecast & Estimates

26 analysts have analysed LEGN and the average price target is 77.3 USD. This implies a price increase of 135.53% is expected in the next year compared to the current price of 32.82.

For the next year, analysts expect an EPS growth of 7.73% and a revenue growth 68.18% for LEGN


Analysts
Analysts83.08
Price Target77.3 (135.53%)
EPS Next Y7.73%
Revenue Next Year68.18%

LEGN Ownership

Ownership
Inst Owners47.87%
Ins Owners0.08%
Short Float %8.68%
Short Ratio6.49